TY - JOUR TI - Engineered cells as glioblastoma therapeutics AU - Ramanathan, Aparna AU - Lorimer, Ian A. J. T2 - Cancer Gene Therapy AB - In spite of significant recent advances in our understanding of the genetics and cell biology of glioblastoma, to date, this has not led to improved treatments for this cancer. In addition to small molecule, antibody, and engineered virus approaches, engineered cells are also being explored as glioblastoma therapeutics. This includes CAR-T cells, CAR-NK cells, as well as engineered neural stem cells and mesenchymal stem cells. Here we review the state of this field, starting with clinical trial studies. These have established the feasibility and safety of engineered cell therapies for glioblastoma and show some evidence for activity. Next, we review the preclinical literature and compare the strengths and weaknesses of various starting cell types for engineered cell therapies. Finally, we discuss future directions for this nascent but promising modality for glioblastoma therapy. DA - 2021/03/22/ PY - 2021 DO - 10.1038/s41417-021-00320-w DP - www.nature.com SP - 1 EP - 11 LA - en SN - 1476-5500 UR - https://www.nature.com/articles/s41417-021-00320-w Y2 - 2021/03/23/20:00:22 ER -